Vocxi Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vocxi Health is pioneering a transformative, non-invasive diagnostic platform centered on its MyBreathPrint® system. Inspired by canine olfaction, the technology uses a proprietary sensor array and machine learning to detect disease-specific VOC patterns in breath with parts-per-billion sensitivity, initially targeting lung cancer. The company, a spin-out from a medical device leader and world-class research hospital, is in the clinical validation stage and has garnered significant recognition through awards and nominations, positioning itself to disrupt traditional screening paradigms.

Oncology

Technology Platform

MyBreathPrint®: A non-invasive breath analysis platform using a proprietary sensor array to detect disease-specific volatile organic compound (VOC) patterns at parts-per-billion sensitivity, analyzed by a cloud-based machine learning engine.

Opportunities

The platform addresses a massive unmet need in lung cancer screening by offering a rapid, non-invasive triage tool for indeterminate pulmonary nodules, potentially improving CT scan efficacy.

Its scalable, single-hardware design allows for expansion into detecting a wide range of other diseases, creating a large, multi-indication total addressable market in breath-based diagnostics.

Risk Factors

Key risks include the need for large-scale clinical validation to prove efficacy and secure regulatory clearance (FDA), the technical challenge of ensuring consistent accuracy across diverse patient populations and settings, and competition from other entities developing breath-based or liquid biopsy diagnostics.

Competitive Landscape

Vocxi operates in the emerging breath biopsy/volatolomics space, competing with other startups and academic initiatives developing VOC-based diagnostics. It also faces indirect competition from advancing liquid biopsy technologies and improvements in imaging. Its competitive edge lies in its specific sensor technology, extensive patent portfolio, and focus on clinical integration for lung nodule management.

More companies in Diagnostics & Precision Medicine →More companies in United States →